Advertisement

Studying the Pro-Migratory Effects of MIF

  • Adrian Hoffmann
  • Leon Christian Zwißler
  • Omar El BounkariEmail author
  • Jürgen BernhagenEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2080)

Abstract

Macrophage migration inhibitory factor (MIF) is an upstream regulator of innate immunity and dysregulated MIF is a key mediator of acute and chronic inflammatory processes, autoimmune and cardiovascular diseases, as well as cancer. MIF is a pleiotropic cytokine with chemokine-like functions that has been designated as an atypical chemokine (ACK). It orchestrates leukocyte recruitment and migration into inflamed tissues through non-cognate interactions with the classical chemokine receptors CXCR2 and CXCR4, pathways that are further facilitated by MIF’s cognate receptor CD74. Here, we describe two complementary methods that can be used to characterize immune cell migration and motility responses controlled by MIF and its receptors. These are the Transwell filter migration assay, also known as modified Boyden chamber assay, a two-dimensional (2D) device, and a matrix-based three-dimensional (3D) chemotaxis assay. The Transwell system is primarily suitable to study chemotactic cell transmigration responses toward a chemoattractant such as MIF through a porous filter membrane. The 3D chemotaxis setup enables for the cellular tracking of migration, invasion, and motility of single cells using live cell imaging.

Key words

Macrophage migration inhibitory factor MIF Chemotaxis Chemokinesis Migration Motility Invasion Transwell migration 3D chemotaxis Atypical chemokine Boyden chamber μ-Slide chemotaxis Inflammation 

Notes

Acknowledgements

This work was supported by the Metiphys scholarship of the Ludwig-Maximilians-University (LMU) Munich to A.H. and by Deutsche Forschungsgemeinschaft (DFG) grants SFB1123-A03, BE 1977/10-1, and BE 1977/11-1 to J.B. It was co-supported by the Wilhelm-Sander-Stiftung grant 2017.009.1 and the Else-Kröner-Fresenius-Stiftung (EKFS) grant 2014/A216 to J.B. as well as by DFG under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198) to J.B. We thank ibidi GmbH (Martinsried, Germany) for providing us with the original figures illustrating the 3D μ-Slide chemotaxis assay.

References

  1. 1.
    Bourne HR, Weiner O (2002) A chemical compass. Nature 419(6902):21CrossRefGoogle Scholar
  2. 2.
    David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56(1):72–77CrossRefGoogle Scholar
  3. 3.
    Bloom B, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82CrossRefGoogle Scholar
  4. 4.
    Bernhagen J et al (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365(6448):756–759CrossRefGoogle Scholar
  5. 5.
    Weiser WY et al (1989) Molecular cloning of cDNA encoding a human macrophage migration inhibtion factor. Proc Natl Acad Sci U S A 86:7522–7526CrossRefGoogle Scholar
  6. 6.
    Bernhagen J et al (1996) An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 183(1):277–282CrossRefGoogle Scholar
  7. 7.
    Bernhagen J et al (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13(5):587–596CrossRefGoogle Scholar
  8. 8.
    Calandra T et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377(6544):68–71CrossRefGoogle Scholar
  9. 9.
    Calandra T et al (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6(2):164–170CrossRefGoogle Scholar
  10. 10.
    Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3(10):791–800CrossRefGoogle Scholar
  11. 11.
    Donnelly SC et al (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3:320–323CrossRefGoogle Scholar
  12. 12.
    Morand EF, Leech M, Bernhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5(5):399–410CrossRefGoogle Scholar
  13. 13.
    Tilstam PV et al (2017) MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opin Ther Targets 21(7):671–683CrossRefGoogle Scholar
  14. 14.
    Zernecke A, Bernhagen J, Weber C (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117(12):1594–1602CrossRefGoogle Scholar
  15. 15.
    Leng L et al (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197(11):1467–1476CrossRefGoogle Scholar
  16. 16.
    Alampour-Rajabi S et al (2015) MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis. FASEB J 29(11):4497–4511CrossRefGoogle Scholar
  17. 17.
    Sinitski D et al (2019) Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation. Thromb Haemost 119(4):553–566CrossRefGoogle Scholar
  18. 18.
    Kapurniotu A, Gokce O, Bernhagen J (2019) The multitasking potential of alarmins and atypical chemokines. Front Med (Lausanne) 6:3CrossRefGoogle Scholar
  19. 19.
    Tillmann S, Bernhagen J, Noels H (2013) Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol 4:115CrossRefGoogle Scholar
  20. 20.
    Boyden S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466CrossRefGoogle Scholar
  21. 21.
    Biswenger V et al (2018) Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly sensitive assay system. PLoS One 13(9):e0203040CrossRefGoogle Scholar
  22. 22.
    Zengel P et al (2011) mu-slide chemotaxis: a new chamber for long-term chemotaxis studies. BMC Cell Biol 12:21CrossRefGoogle Scholar
  23. 23.
    Pepperell EE, Watt SM (2013) A novel application for a 3-dimensional timelapse assay that distinguishes chemotactic from chemokinetic responses of hematopoietic CD133(+) stem/progenitor cells. Stem Cell Res 11(2):707–720CrossRefGoogle Scholar
  24. 24.
    Bernhagen J et al (1994) Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration Inhibitory factor (MIF). Biochemistry 33:14144–14155CrossRefGoogle Scholar
  25. 25.
    Klasen C et al (2014) MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol 192(11):5273–5284CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Vascular Biology, Institute for Stroke and Dementia Research (ISD)Klinikum der Universitaet Muenchen (KUM), Ludwig-Maximilians-University (LMU)MunichGermany
  2. 2.Department of AnaesthesiologyKlinikum der Universitaet Muenchen (KUM), Ludwig-Maximilians-University (LMU)MunichGermany
  3. 3.Munich Heart AllianceMunichGermany
  4. 4.Munich Cluster for Systems Neurology (SyNergy)MunichGermany

Personalised recommendations